Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Blood biomarker may predict Parkinson’s disease progression

Publish date:: September 10, 2020

Key clinical point: Neurofilament light chain is the first blood biomarker for Parkinson’s disease progression.

Major finding: Neurofilament light chain in the cerebrospinal fluid can distinguish Parkinson’s disease from multiple system atrophy and progressive supranuclear palsy.

Study details: A retrospective analysis of 514 serum samples).

Disclosures: The study was funded by the Michael J. Fox Foundation for Parkinson’s Research. Dr. Vaou had no relevant financial disclosures.

Citation:

Mollenhauer B et al. Mov Disord. 2020 Aug 15. doi: 10.1002/mds.28206.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Movement Disorders

Blood biomarker may predict Parkinson’s disease progression,

Can DBS in early Parkinson’s disease reduce disease progression?,

Huntington's disease biomarkers appear 24 years before clinical symptoms,

Nilotinib is safe in moderate and advanced Parkinson’s disease,

GI symptoms in Parkinson’s disease correlate with less microbial diversity,